Robert W. Baird downgrades Biogen Idec (Nasdaq: BIIB) from Buy to Neutral, citing Tysabri's disappointing performance and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE